DrugPatentWatch Database Preview

Details for Patent: 8,835,501

Which drugs does patent 8,835,501 protect, and when does it expire?

Patent 8,835,501 protects BELEODAQ and is included in one NDA.

This patent has thirty-six patent family members in twenty-six countries.

Summary for Patent: 8,835,501

Title:	Pharmaceutical formulations of HDAC inhibitors
Abstract:	This invention pertains to pharmaceutical compositions comprising certain carbamic acid compounds (e.g., which inhibit HDAC (histone deacetylase) activity) (e.g., PXD-101, N hydroxy-3-(3-phenylsulfamoyl-phenyl)-acrylamide)) and one or more additional ingredients selected from cyclodextrin, arginine, and meglumine. The present invention also pertains to the use of such compositions, for example, in the inhibition of HDAC, and in the treatment of conditions mediated by HDAC, cancer, proliferative conditions, psoriasis, etc.
Inventor(s):	Bastin; Richard J. (Waterford, IE), Hughes; Nicholas J. (Swindon, GB)
Assignee:	TopoTarget UK Limited (Abingdon, Oxfordshire, GB)
Application Number:	11/913,191
Patent Claim Types: see list of patent claims	Composition; Compound; Formulation; Dosage form; Device;

Drugs Protected by US Patent 8,835,501

Glossary

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Patent Submitted
Spectrum Pharms	BELEODAQ	belinostat	POWDER;IV (INFUSION)	206256-001	Jul 3, 2014		RX	Yes	Yes	➤ Sign Up	➤ Sign Up	Y				➤ Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Patent Submitted

Foreign Priority and PCT Information for Patent: 8,835,501

PCT Information
PCT Filed	May 11, 2006	PCT Application Number:	PCT/GB2006/001737
PCT Publication Date:	November 16, 2006	PCT Publication Number:	WO2006/120456

Non-Orange Book US Patents Family Members for Patent 8,835,501

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Patent No.	Title	Estimated Patent Expiration
9,856,211	Pharmaceutical formulations of HDAC inhibitors	➤ Sign Up
Patent No.	Title	Estimated Patent Expiration

International Patents Family Members for US Patent 8,835,501

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Country	Document Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Canada	2606598	➤ Sign Up
China	101189003	➤ Sign Up
China	102579417	➤ Sign Up
Cyprus	1112498	➤ Sign Up
Country	Document Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration

Summary for Patent: 8,835,501

Foreign Priority and PCT Information for Patent: 8,835,501

For more information try a trial or see the plans and pricing